Investor Announcements - 2012

Interim results

24^th Sep 2012

EKF announces 2012 Interim Results.

HemoCue settlement agreement

10^th Aug 2012

EKF Diagnostics announces that subsidiaries of EKF have entered into a Settlement Agreement with HemoCue AB and HemoCue Inc in relation to patent-related litigation in Germany and the US.

Licensing Agreement for Kidney Markers

17^th Jul 2012

EKF Diagnostics announces that it has signed an exclusive license agreement with the Joslin Diabetes Center (“Joslin”).

Disposal of International Brand Licensing AG

27^th Mar 2012

EKF Diagnostics announces that it has sold its Swiss subsidiary, International Brand Licensing AG for a cash consideration of £50,000, payable over a two year period.

Final results for the year ended 31 December 2011

21^st Mar 2012

EKF Diagnostics announces its audited final results for the year ended 31 December 2011, a year of continued progress.

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.